Wedbush Reaffirms Outperform Rating for Achaogen Inc (AKAO)

Achaogen, Inc. (NASDAQ:AKAO) belonging to the Medical sector has declined -11.29% and closed its last trading session at $22.4.

The 8 analysts offering 12-month price forecasts for Achaogen Inc have a median target of 29.00, with a high estimate of 31.00 and a low estimate of 23.00. Post opening the session at $23.31, the shares hit an intraday low of $22.2 and an intraday high of $24.68 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

AKAO has been the subject of several other reports. Zacks Investment Research upgraded shares of Achaogen from a "hold" rating to a "buy" rating and set a $17.00 price objective on the stock in a research report on Monday, January 9th.

Achaogen, Inc. (NASDAQ:AKAO) yearly performance is 518.78%.

The South San Francisco, California-based company said it had a loss of $1.04 per share. These holdings make up 87.83% of the company's outstanding shares. They set a "positive" rating for the company. The correct version of this report can be viewed at There may be various price targets for a stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Guggenheim reissued a "buy" rating and issued a $30.00 price target on shares of Achaogen in a research report on Tuesday, January 24th. To measure price-variation, we found AKAO's volatility during a week at 6.31% and during a month it has been found around 5.68%. Achaogen, Inc. has a 52-week low of 2.59 and a 52-week high of 27.79.

Achaogen, Inc. (NASDAQ:AKAO)'s distance from 200 day simple moving average is 212.12 percent, its distance from 50 day simple moving average is 38.44 percent, while its distance from 20 day simple moving average is 12.85 percent. NEA Management Company, LLC is the second biggest holder with 5 million shares now valued at 67.90 million whilst Baker Bros Advisors LP has 5 million shares valued at 59.66 million.

Whereas they predicted High and Low Earnings Estimate as $-0.28 and $-0.85 respectively. The company posted revenue of $10.73 million in the period, compared to analysts expectations of $13.33 million. During the same quarter in the previous year, the company posted $-0.61 EPS. The firm's revenue was up 130.3% on a year-over-year basis.

In other news, major shareholder Equity Opportunities Iv Growth bought 500,000 shares of the stock in a transaction on Monday, December 19th. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The stock grabbed 51 new institutional investments totaling 6,654,185 shares while 10 institutional investors sold out their entire positions totaling 2,297,058 shares. Gabelli Funds LLC raised its stake in Achaogen by 19.3% in the fourth quarter. Spark Investment Management LLC now owns 143,865 shares of the biopharmaceutical company's stock worth $689,000 after buying an additional 128,765 shares during the last quarter. Finally, Baker BROS. Advisors LP bought a new stake in shares of Achaogen during the third quarter worth $479,000. Finally, Redmile Group LLC bought a new position in shares of Achaogen during the third quarter worth approximately $155,000. Corporate insiders own 13.80% of the company's stock.

On Dec 16 Achaogen, Inc. The firm discovers, develops, and commercializes novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections.

Related News: